Century Therapeutics, Inc. (IPSC)
Automate Your Wheel Strategy on IPSC
With Tiblio's Option Bot, you can configure your own wheel strategy including IPSC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IPSC
- Rev/Share 1.3357
- Book/Share 2.7951
- PB 0.2212
- Debt/Equity 0.1988
- CurrentRatio 11.6963
- ROIC -0.1181
- MktCap 53263370.0
- FreeCF/Share -1.3267
- PFCF -0.4667
- PE -2.4231
- Debt/Assets 0.1514
- DivYield 0
- ROE -0.1071
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Century Therapeutics (IPSC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Read More
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Read More
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a year ago.
Read More
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Century Therapeutics, Inc. (IPSC)
- IPO Date 2021-06-18
- Website https://www.centurytx.com
- Industry Biotechnology
- CEO Brent Pfeiffenberger
- Employees 140